Literature DB >> 9667830

The joys of in vitro selection: chemically dressing oligonucleotides to satiate protein targets.

B E Eaton1.   

Abstract

Oligonucleotide in vitro selection provides surprisingly specific aptamers to protein targets. Synthetic chemistries for modifying nucleotides have been developed to enhance aptamer binding affinity. The diversity of nucleosides amenable to either triphosphate synthesis or phosphoramidite activation is now sufficiently broad to rival any oligomeric combinatorial library.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9667830     DOI： 10.1016/s1367-5931(97)80103-2

Source DB:  PubMed          Journal:  Curr Opin Chem Biol        ISSN： 1367-5931            Impact factor:   8.822


  15 in total

Review 1.  [Aptamers: a novel approach to intervention studies and development of novel therapeutic approaches].

Authors:  T Ostendorf; J Floege
Journal:  Med Klin (Munich)       Date:  1999-04-15

2.  Escort aptamers: a delivery service for diagnosis and therapy.

Authors:  B J Hicke; A W Stephens
Journal:  J Clin Invest       Date:  2000-10       Impact factor: 14.808

3.  A selection system for identifying accessible sites in target RNAs.

Authors:  W H Pan; H F Devlin; C Kelley; H C Isom; G A Clawson
Journal:  RNA       Date:  2001-04       Impact factor: 4.942

4.  Aptamer database.

Authors:  Jennifer F Lee; Jay R Hesselberth; Lauren Ancel Meyers; Andrew D Ellington
Journal:  Nucleic Acids Res       Date:  2004-01-01       Impact factor: 16.971

5.  Bioimaging of nucleolin aptamer-containing 5-(N-benzylcarboxyamide)-2'-deoxyuridine more capable of specific binding to targets in cancer cells.

Authors:  Kyue Yim Lee; Hyungu Kang; Sung Ho Ryu; Dong Soo Lee; Jung Hwan Lee; Soonhag Kim
Journal:  J Biomed Biotechnol       Date:  2010-03-01

6.  Selection, design, and characterization of a new potentially therapeutic ribozyme.

Authors:  Shawn P Zinnen; Kristal Domenico; Mike Wilson; Brent A Dickinson; Amber Beaudry; Victor Mokler; Andrew T Daniher; Alex Burgin; Leonid Beigelman
Journal:  RNA       Date:  2002-02       Impact factor: 4.942

Review 7.  FDA-Approved Oligonucleotide Therapies in 2017.

Authors:  Cy A Stein; Daniela Castanotto
Journal:  Mol Ther       Date:  2017-03-31       Impact factor: 11.454

Review 8.  In vivo imaging with oligonucleotides for diagnosis and drug development.

Authors:  B Tavitian
Journal:  Gut       Date:  2003-06       Impact factor: 23.059

Review 9.  Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy.

Authors:  Gang Niu; Xiaoyuan Chen
Journal:  Curr Drug Targets       Date:  2010-08       Impact factor: 3.465

10.  Aptamer-based multiplexed proteomic technology for biomarker discovery.

Authors:  Larry Gold; Deborah Ayers; Jennifer Bertino; Christopher Bock; Ashley Bock; Edward N Brody; Jeff Carter; Andrew B Dalby; Bruce E Eaton; Tim Fitzwater; Dylan Flather; Ashley Forbes; Trudi Foreman; Cate Fowler; Bharat Gawande; Meredith Goss; Magda Gunn; Shashi Gupta; Dennis Halladay; Jim Heil; Joe Heilig; Brian Hicke; Gregory Husar; Nebojsa Janjic; Thale Jarvis; Susan Jennings; Evaldas Katilius; Tracy R Keeney; Nancy Kim; Tad H Koch; Stephan Kraemer; Luke Kroiss; Ngan Le; Daniel Levine; Wes Lindsey; Bridget Lollo; Wes Mayfield; Mike Mehan; Robert Mehler; Sally K Nelson; Michele Nelson; Dan Nieuwlandt; Malti Nikrad; Urs Ochsner; Rachel M Ostroff; Matt Otis; Thomas Parker; Steve Pietrasiewicz; Daniel I Resnicow; John Rohloff; Glenn Sanders; Sarah Sattin; Daniel Schneider; Britta Singer; Martin Stanton; Alana Sterkel; Alex Stewart; Suzanne Stratford; Jonathan D Vaught; Mike Vrkljan; Jeffrey J Walker; Mike Watrobka; Sheela Waugh; Allison Weiss; Sheri K Wilcox; Alexey Wolfson; Steven K Wolk; Chi Zhang; Dom Zichi
Journal:  PLoS One       Date:  2010-12-07       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.